抗体药物现状与产业发展前景(16)

. . 并推进我国生物技术产业的发展，提升我国在国际生物制药和生物技术研究中的地位，产生积极的影响。

参考文献及资料来源：

.ebiotrade./emgzf/sepuyuan13/2.htm

/newmedicines/newmedsdb/drugs.cfm?indicationcode=Cervical%20Cance r%7C57

1 《新一代生物技术药物国际论坛-单克隆抗体及疫苗类药物研发及产业化面对的挑战》会刊，中国生物工程学会，200

2 年10月14日，中国，。

2 Janice M. Reichert . Trends in the development of therapeutic anti-cytokine antibodies, Drug Discovery Today, Volume 9, Issue 8, 15 April 2004, Page 34 8

3 Martin J. Glennie and Jan G. J, Renaissance of cancer therapeutic antibodies, Drug Discovery Today, Volume 8, Issue 11, 1 June 2003, Pages 503-510

4 Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under c linical investigation, Cancer Treatment Reviews, Volume 30, Issue 3, May 200 4, Pages 255-268

5 Ying Cao and Laura Lam, Bispecific antibody conjugates in therapeutics, Ad vanced Drug Delivery Reviews, Volume 55, Issue 2, 10 February 2003, Pages 171-197

6 Said Dermimea, David E, David Shaw et al. Vaccine and antibody-directed T cell tumour immunotherapy Biochimica et Biophysica Acta. 2004 1-25

7 Louis-Marie Houdebine, Antibody manufacture in transgenic animals and com parisons with other systems, Current Opinion in Biotechnology, Volume 13, Iss ue 6, 1 December 2002, Pages 625-629

8 Neal S. Rote ,Recurrent pregnancy loss with antiphospholipid antibody: a sys tematic review of therapeutic trials, Obstetrics & Gynecology, Volume 100, Iss ue 1, July 2002, Page 173

9 Veronica Morea, Arthur M. Lesk and Anna Tramontano, Antibody Modeling: Implications for Engineering and Design, Methods, Volume 20, Issue 3, Marc

h 2000, Pages 267-279

10 中国国家食品药品监督管理局（SFDA）：/

word . .